Alpha Cognition (ACOG) versus Its Rivals Financial Contrast

Alpha Cognition (NASDAQ:ACOG) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Alpha Cognition to similar companies based on the strength of its profitability, dividends, risk, institutional ownership, earnings, valuation and analyst recommendations.

Profitability

This table compares Alpha Cognition and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-344.17%
Alpha Cognition Competitors	-2,185.76%	-161.46%	-40.62%

Insider and Institutional Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by company insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Alpha Cognition and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	1	0	3.00
Alpha Cognition Competitors	1922	5378	13921	295	2.59

Alpha Cognition currently has a consensus price target of $20.00, indicating a potential upside of 261.66%. As a group, “Biological products, except diagnostic” companies have a potential upside of 103.08%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Alpha Cognition is more favorable than its competitors.

Risk and Volatility

Alpha Cognition has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500. Comparatively, Alpha Cognition’s competitors have a beta of -3.86, meaning that their average stock price is 486% less volatile than the S&P 500.

Valuation and Earnings

This table compares Alpha Cognition and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Cognition	N/A	-$13.77 million	-2.16
Alpha Cognition Competitors	$574.43 million	-$70.96 million	0.11

Alpha Cognition’s competitors have higher revenue, but lower earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Alpha Cognition beats its competitors on 8 of the 13 factors compared.

About Alpha Cognition

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.